Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Executive Officer

President, Head of R&D

Chief Scientific Officer

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	-
2024-02-07	Premium	acquired	Premium	Premium	Premium	President, Head of R&D
2024-01-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-08-09	Premium	sold	Premium	Premium	Premium	-
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-02	Premium	acquired	Premium	Premium	Premium	-
2023-08-02	Premium	sold	Premium	Premium	Premium	-
2023-07-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-07-10	Premium	sold	Premium	Premium	Premium	-
2023-07-10	Premium	acquired	Premium	Premium	Premium	-
2023-06-13	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-06-09	Premium	acquired	Premium	Premium	Premium	-
2023-06-09	Premium	sold	Premium	Premium	Premium	-
2023-05-09	Premium	acquired	Premium	Premium	Premium	-
2023-05-09	Premium	sold	Premium	Premium	Premium	-
2023-04-10	Premium	sold	Premium	Premium	Premium	-
2023-04-10	Premium	acquired	Premium	Premium	Premium	-

SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SNDX